# LifeLink Ventures

> LifeLink Ventures is a VC fund backing Biotechnology and Health Care. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Barcelona, Spain
- Total investments: 7
- Last investment: Mar 2026
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/lifelink-ventures
- Website: http://www.lifelinkventures.com

LifeLink Ventures is an investment company through which private investors have direct access to exclusive life sciences investments. We look for urgently needed therapies developed by the most driven entrepreneurs and connect them with our network of investors. We believe in the deployment of capital in alignment with a powerful cause –improvement in global health.

## Contacts

5 contacts available for LifeLink Ventures. Shizune tracks 1 team members at LifeLink Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/lifelink-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 71% |
| Health Care | 4 | 57% |
| Therapeutics | 4 | 57% |
| Medical | 2 | 29% |
| Genetics | 2 | 29% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 43% |
| Seed | 2 | 29% |
| Series B | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 43% |
| Switzerland | 1 | 14% |
| United Kingdom | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Francisca Peixoto | Founder & Investment Manager | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Crossbow Therapeutics | Crossbow Therapeutics is a seed-stage, stealth-mode oncology startup company. The company develops antibody engineering for intracellular cancer targets. | $77M | Series B | Mar 18, 2026 |  |
| HAYA Therapeutics | HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $65M | Series A | May 08, 2025 |  |
| Arda Therapeutics | Arda Therapeutics is a biotechnology company taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions. Their approach starts by using single-cell data to identify pathogenic cells and specific markers to target them. They then design therapies to eliminate these - and only these - cells.Arda wasfounded in 2021 in the San Francisco Bay Area, CA. | $43M | Series A | Oct 01, 2024 |  |
| Ochre Bio | Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body.Ochre Bio is within the heartof Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market. | $30M | Series A | Oct 10, 2022 |  |
| Ochre Bio | Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body.Ochre Bio is within the heartof Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market. |  | Series A | Dec 10, 2021 |  |
| Chameleon Biosciences | Chameleon is changing the way they treat genetic diseases using gene therapy to deliver corrective genes using multiple systemic dose administrations.Research indicates that 20-30% of all infant fatalities are due to genetic disorders, and for those who survive, treatment options are often limited. Recent breakthroughs in gene therapy are savinglives, but there's still a long way to go. At Chameleon, their goal is to ensure every child can be treated with lower doses and accurate target specificity over time as their condition requires. They are committed to every child and family who suffers from a genetic disorder. Their mission is to make sure every Belle, Abby and Marian live to their 10th birthdays, learn to drive, go to prom and someday have healthy children of their very own. | $11.1M | Seed | Mar 25, 2021 |  |
| Calyxha Biotechnologies | Calyxha is developing novel therapies targeting tissue degeneration that is the fundamental underlying cause of major human diseases. | $1.1M | Seed | Feb 28, 2020 |  |

7 of 7 investments shown.

## Co-investors
- [Arax Capital Partners](https://shizune.co/investors/profile/arax-capital-partners) — VC Fund, 2 deals together
- [Eli Lilly](https://shizune.co/investors/profile/eli-lilly) — VC Fund, 2 deals together
- [Taiho Ventures](https://shizune.co/investors/profile/taiho-ventures-2) — VC Fund, 2 deals together
- [Acequia Capital (AceCap)](https://shizune.co/investors/profile/acequia-capital) — VC Fund, 1 deal together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 1 deal together
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does LifeLink Ventures invest in?

LifeLink Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact LifeLink Ventures?

Public channels for LifeLink Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at LifeLink Ventures?

The team at LifeLink Ventures includes Francisca Peixoto (Founder & Investment Manager). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co